ERA Test in IVF: History, Evidence, and What NICE, ESHRE, ASRM and HFEA Say Now
Key Takeaways
An ERA test reads a gene-expression profile from a biopsy to suggest personalised transfer timing. The idea grew from limits of microscope dating, but stronger randomised evidence has not shown clear live-birth benefit for most patients. In 2026 NICE recommends not offering endometrial receptivity testing — including ERA and microbiome panels such as EMMA/ALICE — as a transfer add-on.
Key evidence: NICE NG257 — Fertility problems (2026), recommendation 1.41.1 NICE — Evidence review D: endometrial receptivity testing Doyle et al. — randomised trial, JAMA 2022 (PMID 35710597)
After repeated negative transfers, a question often returns: “What if it is not the embryo, but the timing?” That is what an ERA test (endometrial receptivity analysis) claims to clarify. From a biopsy, it reads the implantation window, then suggests moving transfer earlier or later by hours.
The question is fair. What has changed is not only how the test is marketed. It is randomised evidence — and, in 2026, a plain NICE NG257 line: do not offer endometrial receptivity testing as an embryo-transfer add-on.
In this article
- What an ERA test is trying to measure
- How the test was developed
- What an ERA cycle looks like in practice
- What major clinical trials show
- What NICE, ESHRE, ASRM and HFEA say now
- ERA, EMMA, ALICE: what NICE actually covers
- What to review before agreeing to a receptivity biopsy
- Clinical note
- Questions worth asking before you decide
- FAQ
What an ERA test is trying to measure
Short answer: Not “is your uterus fertile?”, but: at this point in the cycle, does the lining’s gene profile look receptive, a bit early, or a bit late?
ERA starts with an endometrial biopsy. The lab compares the expression of many genes with a “receptive” signature. Reports usually label the lining receptive, pre-receptive, or post-receptive. If the window looks shifted, the team may move progesterone start or transfer hour in a later frozen cycle. That is personalised embryo transfer.
Other commercial panels promise much the same idea under other names. The shared promise: turn a painful failure into a timing problem you can “fix”. The hard question remains: does that fix raise live birth?
How the test was developed
Short answer: From unreliable microscope dating, to a patented molecular test widely offered in clinics — then to tougher randomised trials.
Before ERA: dating the lining under the microscope
For a long time, clinicians tried to “date” the endometrium on a slide (Noyes criteria and related systems). The goal was already embryo–lining synchrony. In practice, morphological dating varied a lot between readers. It did little to guide modern IVF transfer timing.
2000–2011: from research to the first ERA
Teams looked for a molecular signature of receptivity in gene expression across the cycle. In 2011, Diaz-Gimeno and colleagues published a clinical tool based on a large gene panel (about 238 at first) and an algorithm that classifies the result: the endometrial receptivity array. An earlier patent and development by Igenomix moved the idea from lab to commercial test.
The starting hypothesis was simple. In some patients with repeated failure, the implantation window might be shifted. Transferring at the “right” time might then help.
After 2011: sequencing, finer timing, ERA + microbiome packs
The test moved to next-generation sequencing and a panel often cited as 248 genes. Results often propose an hour- or day-level progesterone shift for the next cycle. A second biopsy is sometimes asked for to confirm the window.
Later, ERA was offered with microbiome and chronic infectious endometritis panels (EMMA, ALICE) in packs such as EndomeTRIO. That is no longer timing alone. It is a wider endometrial workup — which NICE 2026 places under the same do not offer add-on recommendation.
Why the test spread so fast
Because it offers both an explanation (“your window is shifted”) and a next step (“transfer 12–24 hours earlier or later”). After failure with a good-looking — or euploid — embryo, that story is easy to grasp. The test spread faster than the strongest randomised evidence.
What an ERA cycle looks like in practice
Short answer: A biopsy in a “dress rehearsal” cycle (often hormone-prepared), analysis, then possibly a later frozen transfer timed to the report — not during a stimulated egg-collection cycle.
Typical steps:
- Prepare a mock or programmed cycle as close as possible to the future transfer protocol (often hormone replacement).
- Take an endometrial biopsy after a set number of hours of progesterone.
- Receive a profile (receptive / pre / post) and any recommended shift.
- Repeat a similar preparation for transfer, with adjusted timing.
That adds cost, delay, and sometimes a second biopsy. It is not a casual “while we are here” step before a first transfer.
What major clinical trials show
Short answer: Encouraging signals in some older or mixed studies; no clear live-birth gain in the best-known euploid randomised trial (Doyle 2022) — the one NICE weighed heavily.
| Study or synthesis | Who, how | What it means for you |
|---|---|---|
| Early ERA work and cohorts | Often repeated failure; varied methods | Built the personalised-transfer hypothesis |
| Simon et al. randomised work | Broader IVF population; methods debated | Helped popularity; also drew critique |
| Doyle et al., JAMA 2022 | One euploid frozen blastocyst; ERA timing vs standard | No clear live-birth improvement → not routine use |
| Recent meta-analyses (including J Assist Reprod Genet 2023) | Mixed studies | No clear live-birth or clinical-pregnancy advantage |
| Reviews limited to euploid transfers | Euploid embryo transfers | No clear benefit with ERA |
What matters for an add-on is not a “non-receptive” label on a report. It is live birth in a trial comparable to your situation. On that point, current guidance stays cautious.
What NICE, ESHRE, ASRM and HFEA say now
Short answer: None of these frameworks put ERA in standard care. NICE 2026 goes furthest: do not offer it as an add-on.
| Body | Position, in brief | Link |
|---|---|---|
| NICE (UK), NG257, 2026 | Do not offer endometrial receptivity testing as a transfer add-on — gene-expression tests (e.g. ERA) and microbiological tests (e.g. EMMA, ALICE). Reason: no important benefit shown. | NG257 §1.41.1 · Evidence review D |
| ESHRE (recurrent implantation failure, 2023) | Insufficient evidence for routine commercial receptivity tests; assessing some aspects of endometrial function can be considered case by case — not a green light for everyone. | ESHRE recommendations |
| ASRM (2026 opinion) | Insufficient evidence for routine ERA after repeated implantation failure. | ASRM 2026 opinion |
| HFEA (add-ons) | Rates these tests in its add-on framework; patient message: caution, no clear benefit for wide use. | HFEA page |
Why NICE is so firm
In the NG257 rationale, the committee sees no important difference in clinical pregnancy and live birth between ERA-timed frozen transfer and standard timing. It also notes mixed secondary signals. Practical conclusion: fewer of these tests.
For patients treated outside the UK, NICE is not local law. It is a committee that reviewed the same trials as everyone else — and drew a clear line. Asking your centre how it reads that view is still a fair question.
ERA, EMMA, ALICE: what NICE actually covers
Short answer: Recommendation 1.41.1 is not ERA-only. It also covers microbiological “receptivity” panels.
- ERA (and gene-expression equivalents): timing / implantation window.
- EMMA / ALICE: microbial or infectious endometrial profiles, often sold as a step toward antibiotics or other interventions.
NICE notes a lack of strong evidence for microbiome “test then treat” strategies. It asks for research on those treatments — while still saying do not offer these tests as add-ons today.
Bundling ERA + EMMA + ALICE in one commercial pack does not bypass that view. It widens the scope of caution.
What to review before agreeing to a receptivity biopsy
Short answer: More ordinary explanations for failed transfer deserve attention first.
Before a receptivity test, review:
- embryo quality or ploidy — see IVF embryo grading;
- uterine cavity (polyps, adhesions, septum);
- transfer technique;
- hydrosalpinx;
- chronic endometritis when indicated;
- progesterone route and timing in the actual protocol;
- fresh vs frozen transfer strategy.
If those points have not been covered, an ERA is harder to justify — even after a polished pitch about “personalisation”.
Clinical note
Short answer: Dr. Senai Aksoy: I do not recommend ERA in any patient group — including after repeated failure with euploid blastocysts.
Dr. Senai Aksoy: “I do not offer ERA routinely, and I do not offer it as a ‘last resort’ after several failed transfers either. Current studies have not shown that timing transfer to an ERA report raises live birth compared with standard progesterone timing — including with euploid embryos. Scientific committees do not support routine use. Presenting an invasive, costly test without proven live-birth benefit as a final option, leaning on a patient’s exhaustion, does not feel ethical to me.
What I say in clinic: failed implantation does not prove that your implantation window is shifted. ERA has not been shown to diagnose that reliably, or to improve live birth when timing is changed on its result. I do not recommend spending money and time on this test.
What bothers me most is hearing, after a few negative transfers, ‘your window may have shifted’ — with ERA presented as the missing piece. Scientific uncertainty should be said out loud. Pushing an unproven test through the fear of ‘leaving no stone unturned’ is not good practice.
After cavity factors, possible hydrosalpinx, transfer technique and the embryo have been reviewed, the more rational path is still: start progesterone on the right day and hour, keep dosing consistent, and check serum progesterone when indicated. If failure continues, we revisit the same standardised protocol. We do not move on to ERA.”
Questions worth asking before you decide
Short answer: Concrete questions beat slogans about the implantation window.
- Which definition of repeated implantation failure are you using in my file (ESHRE around 60% cumulative predicted chance, or another)?
- What will change exactly in the next frozen transfer if the report says pre- or post-receptive?
- Have you already set standard progesterone timing without a biopsy?
- How do you read Doyle 2022 and NICE 1.41.1 in my case?
- If transfer still fails after “personalised” timing, what is the next step — not another commercial pack?
FAQ
Does an ERA test improve IVF success for everyone?
No. Current evidence does not support routine use. NICE 2026 recommends not offering it as an add-on.
Is ERA mainly discussed in recurrent implantation failure?
Yes. That is where it comes up most. Even there, ASRM 2026 finds insufficient evidence for routine use, and ESHRE 2023 does not list it as a green recommended investigation for everyone.
Does a non-receptive result prove why previous transfers failed?
No. It may suggest one possible factor. Failed implantation often has more than one cause.
Should an ERA be done before a first embryo transfer?
Usually no. It is not a first-cycle step in current guidance.
How is ERA different from a lining-thickness scan?
Ultrasound thickness and appearance are not the same as gene-expression timing. A thick lining can still be labelled non-receptive on ERA — and the clinical meaning of that label remains debated.
Does NICE ban the test worldwide?
No. NICE mainly guides UK practice. Elsewhere it is a strong evidence landmark, not local law. It is still fair to ask why a centre departs from such a clear “do not offer”.
Sources
- NICE. Fertility problems: assessment and treatment (NG257). 2026. Recommendation 1.41.1.
- NICE. Evidence review D: endometrial receptivity testing. 2026.
- NICE. Rationale and impact — endometrial receptivity testing.
- ESHRE Working Group on Recurrent Implantation Failure. ESHRE good practice recommendations on recurrent implantation failure. Human Reproduction Open. 2023.
- ASRM Practice Committee. Recurrent implantation failure: a committee opinion. 2026.
- Human Fertilisation and Embryology Authority. Endometrial receptivity testing.
- Doyle N et al. Effect of Timing by Endometrial Receptivity Testing vs Standard Timing of Frozen Embryo Transfer on Live Birth…. JAMA. 2022;328(21):2117-2125.
- Zolfaroli I et al. Impact of Endometrial Receptivity Analysis on Pregnancy Outcomes… Systematic Review and Meta-Analysis. J Assist Reprod Genet. 2023.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.